Alembic Pharmaceuticals Gains USFDA Approval for Hypertension Treatment

Alembic Pharmaceuticals received final USFDA approval for its generic Diltiazem Hydrochloride extended-release capsules, designed to treat hypertension. Available in multiple strengths, these capsules can be used solely or with other antihypertensive drugs. They manage chronic stable angina and coronary artery spasm angina with a substantial market size.

Alembic Pharmaceuticals Ltd has announced that it has secured final approval from the US Food & Drug Administration (USFDA) for its generic Diltiazem Hydrochloride extended-release capsules. These capsules are intended to treat hypertension and come in strengths of 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg.

The approval marks a significant development for Alembic, as the capsules can be used alone or alongside other antihypertensive medications. Furthermore, Diltiazem Hydrochloride is also suitable for managing chronic stable angina and angina caused by coronary artery spasm, according to the company.

The market size for Diltiazem Hydrochloride extended-release capsules, as highlighted by IQVIA data, is estimated at USD 105.3 million for the 12 months ending June 2024, signaling robust demand within this pharmaceutical segment.

(With inputs from agencies.)